JAK2 mutation status, hemostatic risk factors and thrombophilic factors in essential thrombocythemia (ET) patients

Folia Histochemica et Cytobiologica

Volumn 49, Issue 2, 2011, Pages 267-271

  Sokolowska, Bozena ^a   Nowaczyńska, Aleksandra ^a   Bykowska, Ksenia ^b   Chocholska, Sylwia ^a   Wejksza, Katarzyna ^c   Walter Croneck, Adam ^a   Gromek, Tomasz ^a   Kowalska, Anna M ^d   Kandefer Szerszeń, Martyna ^c   Dmoszyńska, Anna ^a  

^a MEDICAL UNIVERSITY OF LUBLIN   (Poland)

^b INSTITUTE OF HEMATOLOGY AND TRANSFUSION MEDICINE   (Poland)

^c MARIA CURIE SK ODOWSKA UNIVERSITY   (Poland)

^d CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

Author keywords

Et; JAK2 mutation; Thrombophilic factors

Indexed keywords

ANTITHROMBIN; BLOOD CLOTTING FACTOR 12; BLOOD CLOTTING FACTOR 8 CONCENTRATE; FIBRINOGEN; HOMOCYSTEINE; PROTEIN C; PROTEIN S; UROKINASE; BLOOD CLOTTING FACTOR; JAK2 PROTEIN, HUMAN; JANUS KINASE 2;

ADULT; ARTERY EMBOLISM; ARTERY THROMBOSIS; ARTICLE; BLOOD CLOTTING DISORDER; BRAIN ISCHEMIA; CLINICAL ARTICLE; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; FACTOR V LEIDEN GENE; FEMALE; GASTROINTESTINAL HEMORRHAGE; GENE; HEART INFARCTION; HEMATOLOGICAL PROCEDURES; HUMAN; JAK2 GENE; LEUKOCYTE COUNT; LUNG HEMORRHAGE; MALE; MTHFR GENE; MUTATIONAL ANALYSIS; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PHLEBITIS; PLATELET LYSATE; POINT MUTATION; PORTAL VEIN THROMBOSIS; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTHROMBIN GENE; RISK FACTOR; SPLENECTOMY; STILLBIRTH; THROMBOCYTE COUNT; THROMBOCYTHEMIA; THROMBOSIS; VEIN THROMBOSIS; BLEEDING; CASE CONTROL STUDY; ENZYMOLOGY; GENETIC PREDISPOSITION; GENETICS; HEMOSTASIS; MIDDLE AGED; THROMBOPHILIA;

BLOOD COAGULATION FACTORS; CASE-CONTROL STUDIES; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HEMORRHAGE; HEMOSTASIS; HUMANS; JANUS KINASE 2; MALE; MIDDLE AGED; POINT MUTATION; RISK FACTORS; THROMBOCYTHEMIA, ESSENTIAL; THROMBOPHILIA;

EID: 80055113732     PISSN: 02398508     EISSN: 18975631     Source Type: Journal    
DOI: 10.5603/FHC.2011.0037     Document Type: Article

References (19)

1. Baxter EJ, Scott LM, Campbell PJ et al. Acquired mutation of the thyrosine kinase JAK2 in human myeloproliferative disorders. Lancet. 2005;365:1054-1061.
2. Koksal V, Etlik O, Arican-Baris ST, Baris I. A tetra polymerase chain reaction approach for the detection of JAK2 V617F mutation. Genet Test. 2007;11:463-466.
3. Miller SA, Dykes DD, Polesky HF. A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res. 1988;16:1215.
4. Bertina RM, Koeleman BPC, Koster T et al. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature. 1994;369:64-67.
5. Poort SR, Rosendaal FR, Reitsma PH, Bertina RM. A common genetic variation in the 3'-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis. Blood. 1996;88:3698-3703.
6. Frosst P, Blom HJ, Milos R et al. A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase. Nat Genet. 1995;10:111-113.
7. Dameshek W. Some speculations on the myeloproliferative syndromes. Blood. 1951;6:372-375.
8. Perea G, Remacha A, Besses C, Jimenez M, Florensa L, Cervantes F. Is polycythemia vera a serious disease in young adults? Haematologica. 2001:86:543-544.
9. Levine RL, Wadleigh M, Cools J et al. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell. 2005;7:387-397.
10. Campbell PJ, Scott JM, Buck G et al. Definition of subtypes of essential thrombocythemia and relation to polycythemia vera based on JAK2 V617 F mutation status: a prospective study. Lancet. 2005;366:1945-1953.
11. Jamrozek-Jedlińska M, Grzywacz A, Jedliński I, Zawilska K. Zakrzepica żył jamy brzusznej jako wczesny objaw zespołu mieloproliferacyjnego. Acta Haematol Pol. 2009;40:115-119.
12. Primignani M, Barosi G, Bergamaschi G et al. Role of the JAK2 mutation in the diagnosis of chronic myeloproliferative disorders in splanchnic vein thrombosis. Hepatology. 2006;44:1528-1534.
13. Kiladjian JJ, Cervantes F, Leebeek FW et al. The impact of JAK2 and MPL mutations on diagnosis and prognosis of splanchnic vein thrombosis: a report on 241 cases. Blood. 2008;11:4835-4836.
14. Di Nisio M, Barbui T, Di Gennaro L et al.The haematocrit and platelet target in polycythemia vera. Br J Haematol. 2007;136:249-259.
15. Landolfi R, Di Gennaro L, Falanga A. Thrombosis in myeloproliferative disorders: pathogenetic facts and speculation. Leukemia. 2008;22:2010-2028.
16. Finazzi G, Barbui T. Risk-adapted therapy in essential thrombocythemia and polycythemia vera. Blood Rev. 2005; 19:243-252.
17. Barbui T, Barosi G, Grossi A et al. Practice guidelines for the therapy of essential thrombocythemia. A statement from the Italian Society of Hematology, the Italian Society of Experimental Hematology and the Italian Group for Bone Marrow Transplantation. Haematologica. 2004; 89:215-232.
18. Khandanpour N, Willis G, Meyer FJ et al. Peripheral arterial disease and methylenetetrahydrofolate reductase (MTHFR) C677T mutations. A case-control study and meta-analysis. J Vasc Surg. 2009;49:711-718.
19. McGimpsey SJ, Woodside JV, Cardvell G, Cahil M, Chakravarthy V. Homocysteine, methylenetetrahydrofolate reductase C677T polymorphism, and risk of retinal vein occlusion: a meta-analysis. Ophtalmology. 2009; 116:1778-1787.